openPR Logo
Press release

Non-Alcoholic Steatohepatitis (NASH) global key players AdAlta Ltd, BASF SE, Betagenon AB, ChemoCentryx Inc, CohBar Inc, GRI Bio Inc, MedImmune LLC market analysis and forcast 2018

02-05-2018 02:02 PM CET | Health & Medicine

Press release from: WISE GUY RESEARCH CONSULTANTS PVT. LTD.

/ PR Agency: Wise Guy Research Consultants Pvt. Ltd
Non-Alcoholic Steatohepatitis (NASH)

Non-Alcoholic Steatohepatitis (NASH)

Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H1

Overview

Non-alcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup of fat in the liver. NASH can get worse and cause scarring of the liver, which leads to cirrhosis. Symptoms of NASH include fatigue, weight loss for no clear reason, general weakness and an ache in the upper right part of belly. Risk factors include obesity, type 2 diabetes, high cholesterol and high triglycerides and metabolic syndrome.

Click here for sample report @ https://www.wiseguyreports.com/sample-request/2811463-non-alcoholic-steatohepatitis-nash-pipeline-review-h1-2018

Non-Alcoholic Steatohepatitis (NASH) Industry Major Highlights:

Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The report further guide in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Non-Alcoholic Steatohepatitis (NASH)  report also showcase the therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 32, 28, 6, 84, 35 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Major Outlook of Non-Alcoholic Steatohepatitis (NASH) Report:

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal)

- The pipeline guide reviews pipeline therapeutics for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

Competitive Analysis for Non-Alcoholic Steatohepatitis (NASH)

Key players are making innovative developments in Non-Alcoholic Steatohepatitis (NASH) industry.  The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector.

The key players in this market are: AdAlta Ltd, BASF SE, Betagenon AB, ChemoCentryx Inc, CohBar Inc, GRI Bio Inc, MedImmune LLC, Merck & Co Inc, and Zebra Discovery Ltd.

….. Continued

Table of Contents

Introduction 7

Non-Alcoholic Steatohepatitis (NASH) - Overview 8

Non-Alcoholic Steatohepatitis (NASH) - Therapeutics Development 9

Non-Alcoholic Steatohepatitis (NASH) - Therapeutics Assessment 31

Non-Alcoholic Steatohepatitis (NASH) - Companies Involved in Therapeutics Development 47

Non-Alcoholic Steatohepatitis (NASH) - Drug Profiles 91

Non-Alcoholic Steatohepatitis (NASH) - Dormant Projects 478

Non-Alcoholic Steatohepatitis (NASH) - Discontinued Products 481

Non-Alcoholic Steatohepatitis (NASH) - Product Development Milestones 482

……

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/2811463-non-alcoholic-steatohepatitis-nash-pipeline-review-h1-2018

Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. We also provide COTS (Commercial off the Shelf) business sector reports as custom exploration agreeing your particular needs.

WISEGUY RESEARCH CONSULTANTS PVT LTD
Office No. 528, Amanora Chambers
Pune - 411028
Maharashtra, India

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Non-Alcoholic Steatohepatitis (NASH) global key players AdAlta Ltd, BASF SE, Betagenon AB, ChemoCentryx Inc, CohBar Inc, GRI Bio Inc, MedImmune LLC market analysis and forcast 2018 here

News-ID: 931516 • Views:

More Releases from WISE GUY RESEARCH CONSULTANTS PVT. LTD.

CBD Snack Market 2020- Global Industry Analysis, By Key Players, Segmentation, Trends and Forecast By 2026
CBD Snack Market 2020- Global Industry Analysis, By Key Players, Segmentation, T …
Summary: A new market study, titled “Discover Global CBD Snack Market Upcoming Trends, Growth Drivers and Challenges” has been featured on WiseGuyReports. Introduction “CBD Snack Market” COVID-19, the disease it causes, surfaced in late 2019, and now had become a full-blown crisis worldwide. Over fifty key countries had declared a national emergency to combat coronavirus. With cases spreading, and the epicentre of the outbreak shifting to Europe, North America, India and
Chronic Lymphocytic Leukemia Global Key Players 4SC AG, AbbVie Inc, Baliopharm AG, Celltrion Inc, Debiopharm International SA, Eli Lilly and Co, Market Analysis and Forecast 2017-2022
Chronic Lymphocytic Leukemia Global Key Players 4SC AG, AbbVie Inc, Baliopharm A …
WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2017” Chronic lymphocytic leukemia (CLL) Overview Chronic lymphocytic leukemia (CLL) is a type of cancer that starts from white blood cells (called lymphocytes) in the bone marrow. It then invades the blood. Symptoms usually develop slowly. Symptoms of CLL include abnormal bruising (if platelets are low), fever, infections
Onychomycosis (Tinea Unguium) Global Key Players Almirall SA, Blueberry Therapeutics Ltd, Dermala Inc, Hexima Ltd Kaken, Pharmaceutical Co Ltd Market Analysis and Forecast 2018-2022
Onychomycosis (Tinea Unguium) Global Key Players Almirall SA, Blueberry Therapeu …
WiseGuyReports.com with their unique quality of simplifying the market research study presents a deep diving study report “Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2018” Onychomycosis (Tinea Unguium) Overview Onychomycosis is a chronic fungal infection of the nails caused by dermatophytes. Symptoms include thickened nail that is difficult to cut, brittle or ragged nail, discolored or unsightly nail and pain of the finger or toe with ordinary activities. Treatment includes antifungal medications and
Non Alcoholic Fatty Liver Disease Global Key Players Akcea Therapeutics Inc, Betagenon AB, Cadila Healthcare Ltd, Daewoong Pharmaceutical Co Ltd, Eli Lilly and Co Market Analysis and Forecast 2018-2022
Non Alcoholic Fatty Liver Disease Global Key Players Akcea Therapeutics Inc, Bet …
WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2018” Non Alcoholic Fatty Liver Disease (NAFLD) Overview Non Alcoholic Fatty Liver Disease (NAFLD) this situation arise when individual have too much fats there your liver. There should be little or no fat in a healthy liver and for most people, carrying a small amount of

All 5 Releases


More Releases for NASH

NASH Market Insight and Landscape report
Report Snapshot: NASH is one of the furthermost causes of liver disease worldwide and will probably emerge as the leading cause of end-stage liver disease in the coming years, with the disease affecting both adults and children. The epidemiology and demographic characteristics of NASH vary across different country level. Furthermore, individuals with NAFLD have a high frequency of metabolic comorbidities and could place a growing strain on health-care systems from their
IQ4I Research published “Non-alcoholic steatohepataitis (NASH) Pipeline Analys …
“Non-alcoholic steatohepataitis (NASH) Pipeline Analysis” gives comprehensive insights on the various drugs being developed for the treatment of NASH. The report covers all the drugs that are in various phases of development (Discovery, Preclinical & Clinical). The pipeline focuses on novel pharmacologic drugs & regenerative medicines covering small molecules, antibodies, stem cell therapies, recombinant proteins and RNA-based therapeutics, but excludes symptom relief drugs, generic combinations and supplemental drugs. The report
Growing Prevalence of NASH to Increase Adoption of Therapeutics
"The Report OpportunityAnalyzer: NASH - Opportunity Analysis and Forecasts to 2026 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" MarketResearchReports.biz has itemized the addition of a new market research report to its report repository. The research publication is titled, “Opportunity Analyzer: NASH - Opportunity Analysis and Forecasts to 2026.” The statistical surveying study is a watchful inspection of the general market
OpportunityAnalyzer: NASH - Opportunity Analysis and Forecasts to 2026
First described in 1980, nonalcoholic steatohepatitis (NASH) (ICD-10-CM = K75.81) is a condition that develops as a subgroup of nonalcoholic fatty liver disease (NAFLD) when excessive fat buildup is accompanied by liver cell injury and inflammation. NAFLD is defined by excessive fat accumulation in the form of triglycerides (steatosis) in the liver. Progression of this condition to NASH dramatically increases the risk of cirrhosis, liver failure, and hepatocellular carcinoma, and
04-07-2017 | Arts & Culture
Memphia PR
Nash releases debut EP 'She Don't Know'
London-based singer/songwriter Nash has released his debut EP She Don’t Know. Recorded at the legendary RAK Studios, She Don’t Know has the feel of 60s rock but with a modern twist, leaving the listener hooked throughout and wanting to come back for another listen. She Don’t Know’s leading single CK is an infectious number which is sure to be a hit for 2017. Listening to the Beatles and Jack White growing
Nash Technologies at GITEX/GULFCOMMS 2010
Harvey Nash subsidiary presents expert services to telecom operators in the Middle East, Africa and South Asia region Nürnberg/Germany, 10th September 2010 – For the first time Nash Technologies will be present at GITEX/GULFCOMMS, the largest international trade event for mobile, fixed, IP and satellite communications for the Middle East, Africa and South Asia region, in Dubai from 17th to 21st October 2010 offering its telecom expert services. Nash Technologies will